Characterisation of real‐world patients who discontinued a glucagon‐like peptide‐1 agonist

Abstract Aims The objective of this analysis was to identify the 6‐month discontinuation rate for GLP‐1 analogues, reasons for discontinuation, and characteristics associated with discontinuation. Materials and methods This was a retrospective analysis of adult patients who had an initial GLP‐1 (semaglutide or liraglutide) dispensed between January 1, 2018 and June 30, 2023. The primary outcome was the 180‐day GLP‐1 discontinuation rate, and among those who discontinued, identification of documented reasons for discontinuation. The secondary outcome was the identification of patient characteristics associated with GLP‐1 discontinuation. Results There were 1374 patients included, of whom 436 (31.7%) discontinued GLP‐1 therapy. Common reasons for GLP‐1 discontinuation included: 26.8% with an adverse drug reaction (ADR), 14.4% with a GLP‐1 cost concern, and 11.2% with non‐adherence. Asian/Native American/Pacific Islander races (adjusted odds ratio AOR 2.51; 95% confidence interval CI 1.07–5.91 compared to Whites) and an overweight/obesity indication (AOR 2.46; 95% CI 1.17–5.17 compared to diabetes + overweight/obesity) were associated with GLP‐1 discontinuation. Conclusions 180‐day GLP‐1 discontinuation was prevalent. ADR and cost concerns were primary reasons for discontinuation and health disparities among patients who discontinued were identified. These real‐world findings offer patients, providers, and policymakers evidence of potential barriers to GLP‐1 persistence.